These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 3177534)
1. Synergistic cytotoxicity between dimethyl sulfoxide and antineoplastic agents against ovarian cancer in vitro. Pommier RF; Woltering EA; Milo G; Fletcher WS Am J Obstet Gynecol; 1988 Oct; 159(4):848-52. PubMed ID: 3177534 [TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of dimethyl sulfoxide and antineoplastic combinations against human tumors. Pommier RF; Woltering EA; Milo G; Fletcher WS Am J Surg; 1988 May; 155(5):672-6. PubMed ID: 3369622 [TBL] [Abstract][Full Text] [Related]
3. Synergistic cytotoxicity of combinations of dimethyl sulfoxide and antineoplastic agents against P388 leukemia in CD-F1 mice. Pommier RF; Woltering EA; Milo G; Fletcher WS Anticancer Drugs; 1992 Dec; 3(6):635-9. PubMed ID: 1288734 [TBL] [Abstract][Full Text] [Related]
4. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines. Viale M; Pastrone I; Pellecchia C; Vannozzi MO; Cafaggi S; Esposito M Anticancer Drugs; 1998 Jun; 9(5):457-63. PubMed ID: 9660544 [TBL] [Abstract][Full Text] [Related]
5. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Cuello M; Ettenberg SA; Nau MM; Lipkowitz S Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070 [TBL] [Abstract][Full Text] [Related]
7. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer. Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281 [TBL] [Abstract][Full Text] [Related]
8. Intravesical chemotherapy: combination with dimethyl sulfoxide does not enhance cytotoxicity in vitro. Walker L; Walker MC; Parris CN; Masters JR Urol Res; 1988; 16(4):329-31. PubMed ID: 3176208 [TBL] [Abstract][Full Text] [Related]
9. [Enhancement of antitumor effect of cisplatin on human ovarian cancer by cyclosporin A in vitro and in vivo]. Zhou Y; Chen H; Yang Q Zhonghua Fu Chan Ke Za Zhi; 1996 Jan; 31(1):25-8. PubMed ID: 8758815 [TBL] [Abstract][Full Text] [Related]
10. The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Myers C Semin Oncol; 1984 Sep; 11(3):275-84. PubMed ID: 6385257 [No Abstract] [Full Text] [Related]
11. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Taylor-Harding B; Orsulic S; Karlan BY; Li AJ Gynecol Oncol; 2010 Dec; 119(3):549-56. PubMed ID: 20837358 [TBL] [Abstract][Full Text] [Related]
12. Identification of synergistic combinations of spirogermanium with 5-fluorouracil or cisplatin using a range of human tumour cell lines in vitro. Hill BT; Bellamy AS; Metcalfe S; Hepburn PJ; Masters JR; Whelan RD Invest New Drugs; 1984; 2(1):29-33. PubMed ID: 6540761 [TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells. Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976 [TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor and cytotoxic agents. Effect on squamous carcinoma lines. Gapany M; Dawson DE; Schriever C; Burgess R; Gipple JR; Riggs CE Arch Otolaryngol Head Neck Surg; 1990 Apr; 116(4):436-9. PubMed ID: 2317326 [TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Alberts DS; Young L; Mason N; Salmon SE Semin Oncol; 1985 Sep; 12(3 Suppl 4):38-42. PubMed ID: 3931226 [TBL] [Abstract][Full Text] [Related]
16. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells. Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217 [TBL] [Abstract][Full Text] [Related]
17. Anti-proliferative activity and mechanism of action of titanocene dichloride. Christodoulou CV; Eliopoulos AG; Young LS; Hodgkins L; Ferry DR; Kerr DJ Br J Cancer; 1998 Jun; 77(12):2088-97. PubMed ID: 9649119 [TBL] [Abstract][Full Text] [Related]
18. In-vitro cell growth of human urothelial tumor cell lines under exposure with IL-3, GM-CSF, G-CSF and by combined administration with methotrexate, vinblastine, adriamycin and cisplatin. Block T; Treiber U; Geffken B; Vogel M; Hanauske AR; Busch R; Hartung R Investig Urol (Berl); 1994; 5():91-4. PubMed ID: 7536524 [No Abstract] [Full Text] [Related]
19. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary. Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199 [TBL] [Abstract][Full Text] [Related]
20. [A new in vitro chemosensitivity test. Individualized chemotherapy against ovarian cancer and its clinical effect]. Takamizawa H; Sekiya S; Iwasawa H; Ishige H; Tokita H; Tanaka N Gan To Kagaku Ryoho; 1985 Dec; 12(12):2293-7. PubMed ID: 2416274 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]